Lg Electronics Inc.

Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Enzychem Lifesciences Corporation

Hyundai Motor Company

Kia Motors Corporation

Other

Electronics and Telecommunications Research Institute

Korea Institute of Science and Technology

Sk Planet Co., Ltd.

Korea Telecommunication Authority

Jong Soo Lee

Se Chang Kwon

Yong Soo Lee

Dae Jin Kim

Sung Min Bae

In Young Choi

Sung Youb Jung

Hyung Kyu Lim

Sung Hee Park

Dae Myoung Yun

Sung H Hong

Young Jin Park

Jin Young Kim

Euh Lim Oh

Yong Ho Huh

Seung Won Baek

Sang Oh Lee

Byuong Woo Lee

Byung Kyu Kang

Jae Hun Bang

Jae Min Lee

Young Oh

Jae Yong Lee

Jin Ho Park

Ji Hyung Kim

Jae Young Lee

Ae Nim Pae

Kyung Il Choi

Jae Hyuk Choi

Baek Hee Lee

Yong Seo Cho

Han Ho Lee

Oh Woog Kwon

Hyun Uk Kim

Seung Su Kim

Myung Hyun Jang

Min Hyuk Kwak

Hun Yeong Koh

Ki Young Sohn

Hyun Kyu Park

Hee Seok Jeong

Yo Seob Lee

Joo Hwan Cha

Sang Youn Hwang

Dae Seong Im

Young Eun Woo

Chae Hyun Baek

Mi Kyoung Lee

Ye Sun Han

Ling Ai Shen

Joo Hong Jeong

Myoung Ho Lee

Gyu Ho Chung

Yong Ho Heo

Sung Min Baek

Sung Chul Choi

Woo Jin Jhong

Jung Yeob Park

Byouong Woo Lee

Choi Kyung Seok

Jin Ki Kim

Hong Chul Yun

Jeong Mee Koh

Kyung Seok Choi

Sung Hee Hong

Young Hak Oh

Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Polyethylene glycol derivative and use thereof

The present invention relates to polyethylene glycol derivatives and use thereof.

A system for adjusting properties of a seat for a vehicle, may include thermoelement modules configured to have a structure in which a plurality of flexible thermoelements is connected by conductive wires to each other, and mounted in a seat foam pad of the seat; a property adjustment region input unit configured to select a property adjustment region of the seat foam pad; a property adjustment amount input unit configured to input a target property adjustment amount of the seat foam pad; and a controller connected to the thermoelement modules, the property adjustment region input unit and the property adjustment amount input unit, and configured to control an amount of current supplied to some or all of the flexible thermoelements according to output signals from the property adjustment region input unit and the property adjustment amount input unit.

System and method for adjusting properties of seat for vehicles

A method for preparing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using an organic solvent is provided. A method for preparing a physiologically active polypeptide complex by linking the conjugate with a carrier is provided. The complex shows improved in vivo duration and stability of the physiologically active polypeptide. The method can prepare the conjugate at a lower production cost, and the resulting conjugate shows an extension of in vivo activity at a relatively high level and significantly increase in the blood half-life.

Method for preparing physiologically active polypeptide complex

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Protein complex by use of a specific site of an immunoglobulin fragment for linkage

It is disclosed a method for preparing calteridol used as MRI contrast agents. It provides a method for preparing calteridol comprising: obtaining teridol represented by the following Formula 2 by reacting gadoteridol represented by the following Formula 1 with decomplexing agent; and obtaining calteridol represented by the following Formula 3 by reacting calcium ion with teridol represented by following Formula 2. 

Method for manufacturing calteridol

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Disclosed is a method for producing calcobutrol used as an MRI contrast agent. The method comprises the steps of: obtaining butrol represented by chemical formula 2 in the specification by reacting a gadobutrol represented by chemical formula 1 in the specification and a decomplexing agent; and obtaining a calcobutrol represented by chemical Formula 3 in the specification by reacting butrol with calcium ions.

Method for producing calcobutrol

A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

IgG4 Fc fragment comprising modified hinge region

Disclosed are: an intermediate capable of high-purity synthesis of gadobutrol which can be used as an MRI contrast agent; and a gadobutrol production method using same. The gadobutrol intermediate is represented by Chemical Formula 2 in the specification.

Gadobutrol intermediate and gadobutrol production method using same

The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.

Long-acting insulin or insulin analogue conjugate

An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.

Insulin analogs and use thereof

Provided are a terminal and a service providing device, an electronic wallet system including the same, a control method thereof, and a non-transitory computer readable storage medium having a computer program recorded thereon. That is, according to the present invention, instead of directly sharing a content including personal information displayed in a specific app, such as an electronic wallet app, installed in the terminal with an SNS or the like, the same content, which does not include personal information and is previously stored in the service providing device so as to correspond to the content, is shared through an SNS corresponding to the terminal, so that it is possible to improve convenience of a user and enhance availability of contents.

Terminal and service providing device, electronic wallet system comprising the same, control method thereof, and non-transitory computer readable storage medium having computer program recorded thereon

Insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described.

Growing community of inventors

Hwaseong-si, South Korea

Jong Soo Lee